Gilead Sciences is a global American biopharmaceutical company founded in 1987 and headquartered in Foster City, California.
Gilead Sciences functions with the support from over 8000 employees in 30 plus countries across the globe. Gilead Sciences had a huge leap in the Fortune Global 500 Companies list from 250, in 2014 to 118, in 2015 with Annual revenue of $32.639 billion and a basic EPS of $12.369 have helped Gilead Sciences emerge as the top 8 pharmaceutical company in the world.
As “Advance the care of patients suffering from life-threatening diseases” is its mission, Gilead Sciences has categorized its formulations under the verticals: HIV / AIDS, Hematology and Oncology, Liver diseases, Cardiovascular, Inflammation / Respiratory and Other with 9, 1, 4, 3, 2 and 2 formulations respectively. AmBisome, Tamiflu, Harvoni, Sovaldi, Zydelig and Hipsera are some of the drugs in the current product portfolio of Gilead Sciences.
$3.014 billion R & D expenditure of Gilead Sciences was utilized in commercializing, as soon as possible, the 40 formulations undergoing various phases of trial. The approval of Gilead Sciences’ TAF-based HIV drug, Odefsey by the FDA (Food and Drug Administration) in March 2016 is expected to drive up revenues for Gilead Sciences in the HIV / AIDS vertical in the near future.